var data={"title":"Cefazolin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefazolin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5835?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefazolin-drug-information\" class=\"drug drug_general\">see &quot;Cefazolin: Drug information&quot;</a> and <a href=\"topic.htm?path=cefazolin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefazolin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16329907\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cefazolin For Injection;</li>\n      <li>Cefazolin For Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045881\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (First Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442202\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection</b> (Bradley 2016; <i>Red Book</i> [AAP] 2015): IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &le;2 kg: 25 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &gt;2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;7 days: 25 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 8 to 60 days: 25 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: <b>Note:</b> Dosing based on a pharmacokinetic study in 36 neonates (GA: Median: 37 weeks; range: 24 to 40 weeks; PNA: Median: 9 days; range: 1 to 30 days) (De Cock 2014): IV:</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Body weight &le;2 kg:</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">PNA &le;7 days: 25 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">PNA 8 to 28 days: 25 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Body weight &gt;2 kg:</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">PNA &le;7 days: 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">PNA 8 to 28 days: 50 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical prophylaxis:</b> PNA &gt;72 hours: IV: 30 mg/kg; administer within 60 minutes before procedure (<i>Red Book</i> [AAP 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045874\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cefazolin-drug-information\" class=\"drug drug_general\">see &quot;Cefazolin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infections: 25 to 50 mg/kg/day divided every 8 hours; maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections: 100 to 150 mg/kg/day divided every 8 hours; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, bacterial:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis for dental and upper respiratory procedures: Infants, Children, and Adolescents: IM, IV: 50 mg/kg 30 to 60 minutes before procedure; maximum dose: 1,000 mg/dose (AHA [Wilson 2007]). <b>Note</b>: AHA guidelines (Baltimore 2015) limit the use of prophylactic antibiotics to patients at the highest risk for infective endocarditis (IE) or adverse outcomes (eg, prosthetic heart valves, patients with previous IE, unrepaired cyanotic congenital heart disease, repaired congenital heart disease with prosthetic material or device during first 6 months after procedure, repaired congenital heart disease with residual defects at the site or adjacent to site of prosthetic patch or device, and heart transplant recipients with cardiac valvulopathy).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Children and Adolescents: IV: 100 mg/kg/day in divided doses every 8 hours; usual adult dose: 2,000 mg/dose; maximum daily dose: 12 <b>g</b>/<b>day</b>; treat for at least 4 weeks; longer durations may be necessary; may use with or without gentamicin (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis)</b> (ISPD [Warady 2012]): Limited data available: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Touch contamination of PD line: Intraperitoneal: 125 mg per liter</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Invasive dental procedures: IV: 25 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gastrointestinal or genitourinary procedures: IV: 25 mg/kg administered 60 minutes before procedure; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Intraperitoneal:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent: 20 mg/kg every 24 hours in the long dwell</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous: Loading dose: 500 mg per liter of dialysate; maintenance: 125 mg per liter of dialysate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired pneumonia (CAP), </b>\n      <i>\n        <b>S. aureus</b></i>\n      <b>, methicillin susceptible:</b> Infants &gt;3 months, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours (Bradley 2011); usual maximum dose for severe infections: 2,000 mg/dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue infections, <i>S. aureus</i>, methicillin susceptible (mild to moderate):</b> (IDSA [Stevens 2014]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus</i>, methicillin susceptible skin and soft tissue infections including pyomyositis: IV: 50 mg/kg/day divided every 8 hours; maximum dose: 1,000 mg/dose; higher doses may be required in severe cases; duration of therapy at least 5 days, but longer may be necessary in some cases, eg, febrile and neutropenic patients: 7 to 14 days; pyomyositis: 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus</i>, methicillin susceptible necrotizing infection of skin, fascia, or muscle: IV: 100 mg/kg/day divided every 8 hours; maximum dose: 1,000 mg/dose; continue therapy until surgical debridement no longer necessary, clinical improvement and afebrile for 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Streptococcal, nonpurulent skin infection (cellulitis): IV: 100 mg/kg/day divided every 8 hours; maximum dose: 1,000 mg/dose; duration of therapy at least 5 days, but longer may be necessary in some cases</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Infants, Children, and Adolescents: IV: 30 mg/kg 30 to 60 minutes before procedure, may repeat in 4 hours for prolonged procedure or excessive blood loss (eg, &gt;1,500 mL in adults); maximum dose dependent upon patient weight: Weight &lt;120 kg: 2,000 mg/dose; weight &ge;120 kg: 3,000 mg/dose (Bratzler 2013; <i>Red Book</i> [AAP] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild infection with gram-positive cocci: IV: 250 to 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe infections: IV: 500 to 1,000 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe, life-threatening infections: IV: 1,000 to 1,500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment: IV:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 1,000 to 1,500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (AHA [Baddour 2015]): MSSA in penicillin-allergic (nonanaphylactoid) patients:</p>\n    <p style=\"text-indent:-8em;margin-left:14em;\">Native valve: 2,000 mg every 8 hours for 6 weeks</p>\n    <p style=\"text-indent:-8em;margin-left:14em;\">Prosthetic valve: 2,000 mg every 8 hours for a minimum of 6 weeks (in combination with rifampin for entire course of therapy and gentamicin for the first 2 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Group B streptococcus; maternal dosing (neonatal prophylaxis):</b> IV: 2,000 mg once, then 1,000 mg every 8 hours until delivery (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perioperative prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: IM, IV: 1,000 to 2,000 mg initiated 30 to 60 minutes prior to surgery; may repeat after 2 hours if procedure is lengthy with 500 mg to 1,000 mg intraoperatively, followed by 500 to 1,000 mg every 6 to 8 hours for 24 hours postoperatively</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IDSA recommendations: IV: <b>Note:</b> For most surgical procedures, joint clinical practice guidelines from the American Society of Health-System Pharmacists, Infectious Diseases Society of America, Surgical Infection Society, and Society for Healthcare Epidemiology of America (ASHP/IDSA/SIS/SHEA) recommend a dose of 2,000 mg within 60 minutes prior to surgical incision (for nonobese patients weighing &lt;120 kg); may be repeated intraoperatively in 4 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Obesity:</i> The ASHP/IDSA/SIS/SHEA guidelines recommend that for patients weighing &ge;120 kg, a dose of 3,000 mg within 60 minutes prior to surgical incision should be administered (Bratzler 2013). Alternatively, for patients with BMI &gt;40 kg/m<sup>2</sup>, a single 2,000 mg dose may be sufficient for common general surgical procedures lasting &lt;5 hours; patients enrolled in this multigroup study had a BMI up to a group mean of 55.7 kg/m<sup>2</sup> (Ho 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, pneumococcal:</b> IV: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis against infective endocarditis:</b> IM, IV: 1,000 mg 30 to 60 minutes before procedure. <b>Note:</b> Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection; uncomplicated:</b> IM, IV: 1,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;1 month, Children, and Adolescents: After initial loading dose is administered, modify dose based on the degree of renal impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;70 mL/minute: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 70 mL/minute: Administer 60% of the usual daily dose divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 40 mL/minute: Administer 25% of the usual daily dose divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 5 to 20 mL/minute: Administer 10% of the usual daily dose given every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: 25 mg/kg/dose every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: 25 mg/kg/dose every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy: 25 mg/kg/dose every 8 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: After initial loading dose is administered, modify dose based on the degree of renal impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;55 mL/minute: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 35 to 54 mL/minute: Administer full dose &ge;every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 11 to 34 mL/minute: Administer 50% of usual dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &le;10 mL/minute: Administer 50% of usual dose every 18 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20% to 50%): 500 to 1,000 mg every 24 hours <b>or</b> use 1,000 to 2,000 mg every 48 to 72 hours (Heintz 2009) <b>or </b>15 to 20 mg/kg (maximum dose: 2,000 mg) after dialysis 3 times weekly (Ahern 2003; Sowinski 2001) <b>or</b> 2,000 mg after dialysis if next dialysis expected in 48 hours <b>or</b> 3,000 mg after dialysis if next dialysis is expected in 72 hours (Stryjewski 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH: Loading dose of 2,000 mg, followed by 1,000 to 2,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVHD/CVVHDF: Loading dose of 2,000 mg, followed by either 1,000 mg every 8 hours <b>or</b> 2,000 mg every 12 hours. <b>Note:</b> Dosage of 1,000 mg every 8 hours results in similar steady-state concentrations as 2,000 mg every 12 hours and is more cost effective (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147067\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/50 mL in Dextrose 4% (50 mL); 2 g/100 mL in Dextrose 4% (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/10 mL (10 mL); 2 g/20 mL (20 mL); 1 g/10 mL in NaCl 0.9% (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 1 g (1 ea); 10 g (1 ea); 20 g (1 ea); 100 g (1 ea); 300 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 1 g (1 ea); 10 g (1 ea); 20 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 1 g and Dextrose 4% (1 ea); 2 g and Dextrose 3% (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147051\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045885\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Deep IM injection into a large muscle mass. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: May be administered IVP over 3 to 5 minutes or IV intermittent infusion over 10 to 60 minutes. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147083\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store intact vials at room temperature and protect from temperatures exceeding 40&deg;C. Reconstituted solutions of cefazolin are light yellow to yellow. Protection from light is recommended for the powder and for the reconstituted solutions. Reconstituted solutions are stable for 24 hours at room temperature and for 10 days under refrigeration. Stability of parenteral admixture in D5W, D5LR, D5<sup>1</sup>/<sub>4</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS, D5NS, D10W, LR, or NS at room temperature (25&deg;C) is 48 hours. Stability of parenteral admixture at refrigeration temperature (4&deg;C) is 14 days. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">DUPLEX: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) prior to activation. Following activation, stable for 24 hours at room temperature and for 7 days under refrigeration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">GALAXY: Store at or below -20&deg;C (-4&deg;F). Thawed solution stable for 48 hours at room temperature and for 30 days under refrigeration. Do not refreeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045884\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of susceptible infections involving the respiratory tract, skin and skin structure, urinary tract, biliary tract, bone and joint, genitals, and septicemia (FDA approved in ages &ge;1 month and adults); perioperative prophylaxis (FDA approved in adults); treatment of bacterial endocarditis (FDA approved in adults); has also been used for bacterial endocarditis prophylaxis for dental and upper respiratory procedures; prophylaxis of peritonitis in patients with peritoneal dialysis (PD) catheters undergoing invasive dental procedures, gastrointestinal or genitourinary procedures, touch contamination prophylaxis of PD catheter, and treatment of peritonitis in patients with peritoneal catheters</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147140\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CeFAZolin may be confused with cefoTEtan, cefOXitin, cefprozil, cefTAZidime, cefTRIAXone, cephalexin </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147137\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Localized phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Seizure </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus, skin rash, Stevens-Johnson syndrome </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal cramps, anorexia, diarrhea, nausea, oral candidiasis, pseudomembranous colitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hepatitis, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic: Eosinophilia, leukopenia, neutropenia, thrombocythemia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147073\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefazolin, other cephalosporin antibiotics, penicillins, other beta-lactams, or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147055\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, may occur. If an allergic reaction occurs, discontinue treatment and institute appropriate supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disease, particularly colitis. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298985\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147060\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13124&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: CeFAZolin may decrease the protein binding of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: CeFAZolin may decrease the protein binding of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147063\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5944549\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have not been observed in animal reproduction studies. Cefazolin crosses the placenta. Adverse events have not been reported in the fetus following administration of cefazolin prior to cesarean section. Cefazolin is recommended for group B streptococcus prophylaxis in pregnant patients with a nonanaphylactic penicillin allergy. It is also one of the antibiotics recommended for prophylactic use prior to cesarean delivery and may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, the pharmacokinetics of cefazolin are altered. The half-life is shorter, the AUC is smaller, and the clearance and volume of distribution are increased. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045880\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function periodically when used in combination with other nephrotoxic drugs, hepatic function tests, and CBC; prothrombin time in patients at risk; number and type of stools/day for diarrhea; monitor for signs of anaphylaxis during first dose </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147054\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147072\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely into most body tissues and fluids including gallbladder, liver, kidneys, bone, sputum, bile, pleural, and synovial; CSF penetration is poor </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 80% (Marshall 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IM or IV: Neonates: 3 to 5 hours; Adults: 1.8 hours (IV); ~2 hours (IM) (prolonged with renal impairment) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 0.5 to 2 hours; IV: Within 5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (70% to 80% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323045\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CeFAZolin in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (50 mL): $5.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/100 mL (100 mL): $7.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 g/100 mL (100 mL): $9.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CeFAZolin in Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/100ML 0.9% (100 mL): $8.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/50ML 0.9% (50 mL): $8.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3GM/100ML 0.9% (100 mL): $9.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CeFAZolin Sodium-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/50 mL 5% (50 mL): $8.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/100ML 4% (100 mL): $11.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CeFAZolin Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $1.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $10.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g (1): $37.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 g (1): $114.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 g (1): $348.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $1.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CeFAZolin Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $2.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CeFAZolin Sodium-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g 4% (1): $5.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g 3% (1): $8.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (CeFAZolin in Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/10ML 0.9% (10 mL): $5.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (CeFAZolin Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (10 mL): $4.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/20 mL (20 mL): $6.19</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038553\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alfazole (VN);</li>\n      <li>Altazolin (HR, SI);</li>\n      <li>Azepo (CZ);</li>\n      <li>Azolin (IN);</li>\n      <li>Basocef (DE);</li>\n      <li>Biofazolin (PL);</li>\n      <li>Cefa (TW);</li>\n      <li>Cefacidal (EC, LU, PE, VE, ZA);</li>\n      <li>Cefamezin (AE, EG, HR, JP, KR, RU, SA, TH, TR);</li>\n      <li>Cefarad (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Cefazin (TW);</li>\n      <li>Cefazol (ID, TH);</li>\n      <li>Cefazolina (LB);</li>\n      <li>Cefazoline Panpharma (FR);</li>\n      <li>Cefazovit (PH);</li>\n      <li>Cefizol (TR);</li>\n      <li>Cefzalin (AE);</li>\n      <li>Celmetin (NO);</li>\n      <li>Cizo (PH);</li>\n      <li>Cloviz (PH);</li>\n      <li>Evalin (ID);</li>\n      <li>Fazlin (TZ);</li>\n      <li>Fazolin (TH);</li>\n      <li>Fazolon (BR);</li>\n      <li>Fonvicol (PH);</li>\n      <li>Ilozef (PH);</li>\n      <li>Intrazolina (ES);</li>\n      <li>Izacef (ZA);</li>\n      <li>Kefarin (GR);</li>\n      <li>Kefazin (IL);</li>\n      <li>Kefzol (AT, BE, BF, BJ, CH, CI, ET, GB, GH, GM, GN, HN, HR, HU, IS, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, NL, PK, SC, SD, SL, SN, TN, TZ, UG, VN, ZM, ZW);</li>\n      <li>Kelin (TW);</li>\n      <li>Kofatol (TW);</li>\n      <li>Oricef (TW);</li>\n      <li>Orizolin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Primacef (PE);</li>\n      <li>Reflin (IN, JO, LT);</li>\n      <li>Saifuning (CN);</li>\n      <li>Sratop (AU);</li>\n      <li>Stancef (PH);</li>\n      <li>Stazolin (TW);</li>\n      <li>Tasep (ES);</li>\n      <li>Tazoline (KW, QA);</li>\n      <li>Totacef (EE, HN, HU);</li>\n      <li>Uzolin (TW);</li>\n      <li>Venozol (ID);</li>\n      <li>Volmizolin (SK);</li>\n      <li>Vulmizolin (CZ);</li>\n      <li>Zepilen (BG, HR, LT, NZ, SG, TR);</li>\n      <li>Zofadep (PH);</li>\n      <li>Zolecef (AE, BH, CY, EG, IQ, IR, JO, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Zolecin (KW, QA);</li>\n      <li>Zolidina (PY);</li>\n      <li>Zolival (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahern JW, Possidente CJ, Hood V, et al, &quot;Cefazolin Dosing Protocol for Patients Receiving Long-Term Hemodialysis,&quot; <i>Am J Health Syst Pharm</i>, 2003, 60(2):178-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/12561661/pubmed\" target=\"_blank\" id=\"12561661\">12561661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physiciansm, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &quot;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&quot; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease, revised guidelines from CDC, 2010. <i>MMWR Recomm Rep</i>. 2010; 59(RR-10):1-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/21088663/pubmed\" target=\"_blank\" id=\"21088663\">21088663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Cock RF, Smits A, Allegaert K, et al. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. <i>J Antimicrob Chemother</i>. 2014;69(5):1330-1338.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/24492261/pubmed\" target=\"_blank\" id=\"24492261\">24492261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Engelman R, Shahian D, Shemin R, et al, &quot;The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part II: Antibiotic Choice,&quot; <i>Ann Thorac Surg</i>, 2007, 83(4):1569-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/17383396/pubmed\" target=\"_blank\" id=\"17383396\">17383396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, et al, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. <i>Surg Infect (Larchmt)</i>. 2012;13(1):33-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/22316145/pubmed\" target=\"_blank\" id=\"22316145\">22316145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/10318297 /pubmed\" target=\"_blank\" id=\"10318297 \">10318297 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall WF, Blair JE. The cephalosporins. <i>Mayo Clin Proc</i>. 1999;74(2):187-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/10069359/pubmed\" target=\"_blank\" id=\"10069359\">10069359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pickering LK, O'Connor DM, Anderson D, et al, &ldquo;Clinical and Pharmacologic Evaluation of Cefazolin in Children,&rdquo; <i>J Infect Dis</i> 1973, 128(Suppl):S407-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/4744023/pubmed\" target=\"_blank\" id=\"4744023\">4744023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson DC, Cookson TL, and Grisafe JA, &ldquo;Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients,&rdquo; <i>Drug Intell Clin Pharm</i>, 1987, 21(12):985-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/3428165/pubmed\" target=\"_blank\" id=\"3428165\">3428165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sowinski KM, Mueller BA, Grabe DW, et al, &quot;Cefazolin Dialytic Clearance by High-Efficiency and High-Flux Hemodialyzers,&quot; <i>Am J Kidney Dis</i>, 2001, 37(4):766-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/11273877/pubmed\" target=\"_blank\" id=\"11273877\">11273877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/24947530 /pubmed\" target=\"_blank\" id=\"24947530 \">24947530 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible <i>Staphylococcus aureus</i> bacteremia. <i>Clin Infect Dis</i>. 2007;44(2):190-196.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/17173215/pubmed\" target=\"_blank\" id=\"17173215\">17173215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, (32 Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &quot;Prevention of Infective Endocarditis: Guidelines from the American Heart Association: A Guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&quot; <i>Circulation</i>, 2007, 116(15):1736-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13124 Version 173.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F16329907\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045881\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442202\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045874\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147067\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F147051\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045885\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F147083\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045884\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147140\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147137\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147073\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147055\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298985\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147060\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147063\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5944549\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045880\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147054\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F147072\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323045\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038553\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13124|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefazolin-drug-information\" class=\"drug drug_general\">Cefazolin: Drug information</a></li><li><a href=\"topic.htm?path=cefazolin-patient-drug-information\" class=\"drug drug_patient\">Cefazolin: Patient drug information</a></li></ul></div></div>","javascript":null}